Male pattern hair loss is the most common type of hair loss in men, and most of what is sold around it is far less certain than the advertising suggests. This article sets out what UK dermatology bodies say about causes, treatments and realistic timelines, and what the medicines regulator updated in May 2026.
What is male pattern hair loss?
According to the British Association of Dermatologists (BAD), male pattern hair loss, also called androgenetic alopecia, is “the most common type of hair loss in men” and can begin at any time after puberty. It is not a disease of the scalp in the usual sense: the scalp looks normal on examination, symptoms are usually absent, and a few men report itching.
The typical pattern is a receding frontal hairline and thinning on the top of the head, while the sides and back are usually spared. The Primary Care Dermatology Society (PCDS) describes the frontal recession as mainly triangular, followed later by thinning at the vertex, the crown of the head.
It is also worth separating it from normal shedding. The NHS says people can lose between 50 and 100 hairs a day, often without noticing. Shedding in that range is not, on its own, a sign of a problem.
How does hair loss happen in the follicle?
The BAD explains that genetic and hormonal factors combine. A hormone called dihydrotestosterone (DHT) alters the hair follicles in a process known as miniaturisation: hairs become progressively thinner, shorter and lighter until the follicle stops producing hair altogether. The PCDS adds that susceptible follicles become sensitive to DHT, which shortens the growth phase of each hair.
Inheritance matters. The BAD says it can be passed on from either or both parents and that over 190 genes have been identified as contributing. The PCDS notes that sons of balding fathers have an increased risk. That is why a family history is often the main clue in diagnosis, alongside the pattern and history of the loss.
What does the course look like over time?
The BAD is plain that there is no cure. Progression is usually slow, taking years to decades, and an earlier age of onset may mean faster progression. The leaflet also acknowledges that hair loss can affect self-esteem and body image, and recommends talking to a healthcare professional about emotional wellbeing as well as treatment.
| Feature | What UK guidance says |
|---|---|
| Typical pattern | Receding frontal hairline, thinning on top; sides and back spared |
| Main drivers | Genetics and DHT acting on follicles |
| Speed | Slow, over years to decades |
| Scalp symptoms | Usually none; some men report itch |
| Cure | None; treatments work only while used |
What treatments exist, and how long do they take?
The BAD and PCDS agree on the broad picture. Treatments aim to slow loss or encourage some regrowth; none restores a full head of hair, and benefits fade when treatment stops.
Topical minoxidil
The BAD describes 5% minoxidil liquid or foam, applied to the scalp, as a treatment that may slow loss and stimulate growth. It is not available on NHS prescription. Benefit may take at least six months and possibly up to 12, and some shedding in the first four to six weeks can occur. The PCDS estimates that it benefits around 40% of patients, works best when started early, and does not change the natural course of the condition. The scalp returns to its original state if treatment is stopped.
Finasteride and dutasteride
Finasteride tablets reduce DHT. The BAD says benefit usually needs up to 14 months of continuous use, and that hair loss restarts after stopping. It reports decreased libido and erectile problems in approximately 2% of patients. The PCDS gives a more optimistic estimate of benefit, suggesting that up to 90% of patients may benefit, and notes that sexual side effects may persist after stopping. It also points out that these drugs lower the PSA blood test used in prostate checks, so the true level may be twice the reported value, something any clinician needs to know.
Dutasteride reduces DHT more strongly, but the BAD says improvement beyond finasteride has not been convincingly shown and that side effects are more frequent and longer-lasting.
The two bodies’ figures differ, which is itself a useful reminder: estimates of benefit depend on how it is measured and over what period. The NHS says that finasteride and minoxidil do not work for everyone and only work for as long as they are used, and that women should not use finasteride.
Newer and less established options
The BAD says recent research suggests low-dose oral minoxidil may be at least as effective as topical treatment in certain cases, with few side effects. The PCDS lists contraindications and notes that excess facial or body hair growth is its commonest adverse effect, reported in 14% of cases. For platelet-rich plasma, microneedling and low-level laser light, the BAD describes evidence as limited or insufficient, and says the first two are not NHS treatments. The PCDS reports that studies of infrared light show no statistical improvement.
What did the MHRA change in May 2026?
On 11 May 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) published updated safety advice on finasteride and dutasteride. According to the MHRA:
- the finasteride 1 mg product information is strengthened to say that sexual dysfunction may contribute to mood disorders, and that mood changes have been reported with and without sexual side effects;
- a precautionary warning is being added to dutasteride 0.5 mg, which is used for benign prostatic hyperplasia, because mood changes have been reported with finasteride, a medicine in the same class;
- the patient alert cards introduced for finasteride in 2024 remain in place, covering sexual dysfunction, depression and suicidal thoughts;
- patients who have depression or suicidal thoughts while taking finasteride should stop treatment and seek medical advice, and concerns about sexual side effects should be discussed with a healthcare professional;
- suspected side effects can be reported through the Yellow Card scheme.
The MHRA said the changes followed an additional review of the evidence, a European review and advice from the Commission on Human Medicines. The practical point is not that the medicine is unsuitable for everyone, but that a decision to use it should be made with a prescriber who has gone through the risks.
Is a hair transplant a realistic alternative?
Hair transplantation is not offered on the NHS and is available privately, according to the BAD. Follicles are taken from the back and sides of the scalp, where they are more resistant to DHT, and moved to balding areas. The PCDS says outcomes are better in men than in women, depend on adequate donor hair, vary with the surgeon’s skill and are very expensive.
The NHS is cautious about commercial claims and advises seeing a GP first to find the likely cause of hair loss before considering a commercial hair clinic. That matters because not all hair loss is pattern loss. The NHS lists temporary causes including illness, stress, cancer treatment, weight loss and iron deficiency, where hair often regrows once the cause is treated.
What are the non-medical options?
Many men choose not to treat it at all, and the PCDS says that is a legitimate decision. Others change how they style it, and a close crop or shaved head is a common route; the practical side of that is covered in our guide to shaving without irritation.
Other options include:
- Wigs and hairpieces. The BAD says synthetic wigs are generally the only type available on the NHS and usually last about six to nine months; real-hair options look more natural and are cooler to wear. The NHS puts real-hair wigs at three to four years, at higher cost.
- Camouflage sprays and fibres. The BAD says sprays may disguise loss but can wash away with water or sweat, and the PCDS notes that products containing nanofibres can give the appearance of thicker hair.
- Sun protection. The BAD advises protecting bald areas from the sun with sunblock, a wig or a hat. Our explainer on SPF and UVA stars covers how to read the label.
Cut and shape can help too. A good barber can work with thinning rather than against it, in the same spirit as the fit principles in how a suit should fit: what flatters is usually what is proportionate.
When should you see a GP?
The NHS advises a non-urgent GP appointment if you are worried about hair loss, and says to mention it if it affects your wellbeing. A GP can look at the pattern, ask about family history, medicines and recent illness, and consider whether tests are needed to rule out other causes. Patchy loss, sudden shedding, scalp redness, scaling or pain, or loss that comes with other symptoms, are all reasons not to assume it is simply pattern loss.
If you are considering finasteride, ask about the alert card and what to do if your mood or sexual function changes. If you already have a history of depression, tell the prescriber before starting, as the MHRA advises.
A sensible way to approach the decision
The evidence is consistent on a few points. Male pattern hair loss is common, hereditary and slow. Treatments can slow it for some men and cannot cure it, and they work only while used. Benefit takes the better part of a year to judge. Medicines carry real trade-offs that deserve a proper conversation. And for many men, doing nothing, or styling around it, is a perfectly reasonable choice.
Since no treatment is likely to be quick, the best first step is usually a measured one: confirm the cause, understand the options and timelines, and decide with a professional rather than a sales page.
This article is general information, not medical advice. If you are worried about hair loss, or have low mood or sexual side effects while taking any medicine, speak to a pharmacist or GP.
Sources: British Association of Dermatologists (Hair loss male pattern (androgenetic alopecia)); Primary Care Dermatology Society (Male pattern alopecia and female pattern alopecia); NHS (Hair loss); NHS (Hair loss: treatment); GOV.UK, MHRA (MHRA strengthens safety warnings for finasteride and dutasteride)
